Related Experiment Video
Updated: Mar 12, 2026

10:28
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
16.4K
Interventions in Parkinson's disease: Role of executive function
Abhimanyu Mahajan1, Jennifer A Deal2, Michelle Carlson2
1Department of Neurology, Henry Ford Hospital, Detroit, MI, amahaja1@hfhs.org.
Frontiers in Bioscience (Landmark Edition)
|November 5, 2016
Summary
Parkinson's disease (PD) interventions like medication, exercise, and Deep Brain Stimulation (DBS) impact executive functions (EF) differently. Further research is needed to precisely measure EF
Area of Science:
- Neuroscience
- Neurology
- Cognitive Science
Background:
- The cortico-striatal network is crucial for executive functions (EF) and implicated in Parkinson's disease (PD) pathophysiology.
- Current tools for assessing EF in PD are limited.
- Understanding EF's role in PD is vital for treatment.
Purpose of the Study:
- To review the impact of pharmacotherapy, physical exercise, and Deep Brain Stimulation (DBS) on executive functions (EF) in Parkinson's disease (PD).
- To identify factors influencing the effects of these interventions on EF.
- To highlight the need for improved EF assessment methods in PD.
Main Methods:
- Systematic review of studies on PD interventions and their effects on EF.
- Analysis of how drug class, exercise type, and DBS parameters influence EF outcomes.
- Evaluation of current neuropsychological tests used for EF assessment in PD.
Main Results:
- Pharmacotherapy effects on EF are variable, depending on drug class, test used, and dopamine receptor involvement.
- Aerobic exercise shows potential benefits for EF, including attention and judgment.
- DBS effects on EF may depend on stimulation site, testing methods, and patient's pre-operative cognitive status.
Conclusions:
- Interventions for PD have varied effects on executive functions.
- More precise EF assessment tools, focusing on the motor aspects of EF, are required.
- Further investigation is needed to clarify the relationship between EF, PD manifestations, and motor recovery.
More Related Videos
Related Concept Videos
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Role of Cerebellum and Prefrontal Cortex in Memory
1.4K
The cerebellum, while traditionally associated with motor control, also plays a crucial role in memory, particularly in procedural memory, which involves learning motor tasks that become automatic through repetition. For example, studies have shown that when the cerebellum is damaged, individuals or animals lose the ability to learn conditioned motor responses, such as the conditioned eye-blink response in classical conditioning experiments with rabbits. This study demonstrates the...
1.4K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Neural Regulation
44.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.0K

